相关实验视频
Updated: Jun 28, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.5K
实施一项安全计划倡议,用于监测多发性硬化症的输液疾病修饰疗法
Shuvro Roy1,2, Janel Haughton, Dhanajay Vaidya
1Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.
概括
一名安全护士导航员改善了输注疾病修饰疗法 (DMT) 的多发性硬化症 (MS) 患者的监测. 该计划成功地发现并解决了基本安全检查中的差距,防止了潜在的并发症.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 患者安全 患者安全
背景情况:
- 输液疾病修饰疗法 (DMT) 对多发性硬化症 (MS) 治疗至关重要.
- 这些先进疗法的安全管理需要严格监测.
- 如果不遵守安全协议,可能会导致严重的DMT相关并发症.
研究的目的:
- 评估专门的安全计划的有效性,用于监测MS患者的输液DMT.
- 确定在输注DMT的患者安全监测的具体缺陷.
- 评估旨在纠正不完整安全监测的干预措施的成功率.
主要方法:
- 一名安全护士导航员在2020年11月至2022年12月期间审查了输注DMT的患者病历.
- 患者被评估为不完整的安全监测,包括过时的实验室,成像和神经科医生随访.
- 使用后勤回归分析来确定不完整监测和成功干预的预测因素.
主要成果:
- 在343名注入DMT的患者中,83%的安全监测不完全.
- 常见的缺陷包括过时的安全实验室 (64%),缺乏处方者随访 (47%) 和缺失的MRI扫描 (26%).
- 导航护士在82%的患者互动中取得了成功的干预,与B细胞耗尽剂和纳塔利祖马布相关的特定监测差距.
结论:
- 安全倡议强调了对MS的输液DMT管理中的重大差距.
- 安全护士导航员模型有效地识别和纠正不完整的安全监控.
- 该计划成功地减轻了接受DMT治疗的MS患者与药物相关并发症相关的风险.
相关概念视频
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...